Researchers have visualized for the first time how the protein SOCS1 ‘switches off’ cell signalling to dampen immune responses and block cancer growth. The atomic-level structure of SOCS1 binding to its partner protein JAK could guide the development of drugs that alter disease-causing cell signalling pathways, and may have applications for treating some blood cancers, including leukaemias.